| Project/Area Number |
24593030
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSUJIGIWA Hidetsugu 岡山理科大学, 理学部, 教授 (70335628)
UNETSUBO Teruhisa 岡山大学, 医歯(薬)学総合研究科, 助教 (30633606)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
OHARA Naoya 岡山大学, 医歯(薬)学総合研究科, 教授 (70223930)
NAGATSUKA Hitoshi 岡山大学, 医歯(薬)学総合研究科, 教授 (70237535)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | BCG / 免疫療法 / 口腔癌 |
|---|
| Outline of Final Research Achievements |
Our aim was to investigate the adjuvant potential of BCG combined with 5-FU for oral cancer. Then, we compared 18F-FDG PET/CT-based molecular imaging evaluation, with corresponding groupwise overall survival, tumor growth and metastasis. Sq-1979 cheek cancer cells were injected subcutaneously into the flank in C3H/HeN mice. After certain growth, tumors were resected and mice were weekly treated with BCG (Tokyo strain; 1 × 106 CFU/mouse) and/or 5-FU. The mice were randomized to four groups. 5-FU along with BCG treatment results in a reduction of recurrence and significantly improved survival. The effects of treatment on 18F-FDG uptake were also studied with those had locally metastatic tumors. This analysis revealed that 5-FU-, 5-FU/BCG-, and BCG-treatment resulted in a reduction of 18-FDG uptake within locally metastatic tumor compared with non-treated mice group. Interestingly, 18F-FDG PET imaging confirmed decreased metabolism even in the xenografts following BCG single treatment.
|
